About US

Based in the Great Bay area, while oriented toward the world

200+

The Core Medical has applied for approximately 200 patents both at home and abroad.

40%

The diameter of the Corheart 6 blood pump is only 34mm, which is 40% smaller than that of similar products in the market.

50%

The Corheart 6 blood pump weighs only 90g, which is 50% less than that of similar products on the market.

200+

The Core Medical has applied for approximately 200 patents both at home and abroad.

40%

The diameter of the Corheart 6 blood pump is only 34mm, which is 40% smaller than that of similar products in the market.

50%

The Corheart 6 blood pump weighs only 90g, which is 50% less than that of similar products on the market.

Shenzhen Core Medical Technology Co., Ltd is a Chinese national high-tech enterprise founded in 2016. Core Medical is dedicated to the research and development of high-end innovative medical devices such as mechanical circulation assist systems.

The Corheart 6 Left Ventricular Assist System (the Corheart 6) is a miniaturized magnetic levitation artificial heart that was independently developed by the Core Medical. The Corheart 6 is an implantable circulatory support system for the treatment of end-stage heart failure. The Corheart 6 is the smallest as well as lightest implantable artificial heart in the world. With a diameter of 34 mm, a thickness of 26 mm, and a weight of 90 g, the blood pump of the Corheart 6 system is 40% smaller in diameter, and 50% lighter compared to existing magnetic levitation artificial heart on the market. The miniaturization design of Corheart 6 makes it applicable to adult and pediatric patients with body surface area larger than 1.0 m2.

In July 2022, the Core Medical completed the clinical trial enrollment for product registration. Follow-up has shown that the Corheart 6 has excellent performance in terms of anti-infection, device reliability, patient recovery, reduced adverse event and improved hemocompatibility.

The Core Medical has applied for approximately 200 patents both at home and abroad. Owing to its remarkable strength in R&D, Core Medical’s innovation achievements in the field of artificial heart is much favored by the capital market. Since 2019, the company has completed three rounds of financing for three consecutive years, and has a steady development momentum.

Innovation

Quality

Value

Company established

2016.08

Completed construction of GMP level 10000 clean room.

2019.05

Obtained A-round Financing from Lianxin capital, Puhua capital and Efung Capital

2020.08

Approval of application for innovative medical devices by the NMPA.

2021.06

Approval of Corheart 6 Clinical trial

2022.01

2019.04

Recieved the First round investment from Hetang Venture Capital.

2019.12

Recognized as a national high-tech enterprise.

2021.05

Obtained B-round Financing from Hillhouse capital and CICC capital
Completed type inspection of the Coreart 6.

2021.10

FIM of the Corheart 6.

2022.07

Corheart 6 clinical trial enrollment completed

2016.08

Company established

2019.04

Recieved the First round investment from Hetang Venture Capital

2019.05

Completed construction of GMP level 10000 clean room

2019.12

Recognized as a national high-tech enterprise

2020.08

Obtained A-round Financing from Lianxin capital, Puhua capital and Efung Capital

2021.05

Obtained B-round Financing from Hillhouse capital and CICC capital
Completed type inspection of the Coreart 6.

2021.06

Approval of application for innovative medical devices by the NMPA

2021.10

FIM of the Corheart 6

2022.01

Approval of Corheart 6 Clinical trial

2022.07

Corheart 6 clinical trial enrollment completed

Company address:16 F, Building D3, Nanshan Zhiyuan phase II, No.4093, LiuXian Avenue, Taoyuan Street, Nanshan District, Shenzhen, Guangdong Province, China.


Contact telephone:0755-23225941